You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 9,803,025


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,803,025
Title:Material and methods for treating or preventing HER-3 associated diseases
Abstract: Described herein are materials and methods for treating subjects having a HER-3 associated disease, by administering a first agent that binds to HER-3, in combination with a second agent that binds and/or inhibits another member of the HER family. The first and the second agent may be a biologic, such as an antigen-binding protein, or a small molecular tyrosine kinase inhibitor, for example.
Inventor(s): Hettmann; Thore (Munchen, DE), Freeman; Daniel J. (Newbury Park, CA), Radinsky; Robert (Thousand Oaks, CA)
Assignee: AMGEN, INC. (Thousand, CA) Daiichi Sankyo Europe GmbH (Munich, DE)
Application Number:13/870,796
Patent Claims:1. A method of treating a cancer associated with HER-3 in a subject, comprising administering to the subject a first agent and a second agent, wherein said first agent is an isolated binding protein which binds to HER-3,- comprising: (a) a heavy chain amino acid sequence that comprises a CDRH1 having the sequence of SEQ ID NO: 236, a CDRH2 having the sequence of SEQ ID NO: 258, and a CDRH3 having the sequence of SEQ ID NO: 283; and a light chain amino acid sequence that comprises a CDRL1 having the sequence of SEQ ID NO: 320, a CDRL2 having the sequence of SEQ ID NO: 343, and a CDRL3 having the sequence of SEQ ID NO: 360; (b) a heavy chain amino acid sequence that comprises a CDRH1 having the sequence of SEQ ID NO: 236, a CDRH2 having the sequence of SEQ ID NO: 258, and a CDRH3 having the sequence of SEQ ID NO: 285; and a light chain amino acid sequence that comprises a CDRL1 having the sequence of SEQ ID No: 320, a CDRL2 having the sequence of SEQ ID NO: 343, and a CDRL3 having the sequence of SEQ ID NO: 360; (c) a heavy chain amino acid sequence that comprises a CDRH1 having the sequence of SEQ ID NO: 251, a CDRH2 having the sequence of SEQ ID NO: 278, and a CDRH3 having the sequence of SEQ ID NO: 309; and a light chain amino acid sequence that comprises a CDRL1 having the sequence of SEQ ID NO: 334, a CDRL2 having the sequence of SEQ ID NO: 356, and a CDRL3 having the sequence of SEQ ID NO: 381; (d) a heavy chain amino acid sequence that comprises a CDRH1 having the sequence of SEQ ID NO: 252, a CDRH2 having the sequence of SEQ ID NO: 280, and a CDRH3 having the sequence of SEQ ID NO: 313; and a light chain amino acid sequence that comprises a CDRL1 having the sequence of SEQ ID NO: 337, a CDRL2 having the sequence of SEQ ID NO: 351, and a CDRL3 having the sequence of SEQ ID NO: 385; or (e) a heavy chain amino acid sequence that comprises a CDRH1 having the sequence of SEQ ID NO: 256, a CDRH2 having the sequence of SEQ ID NO: 282, and a CDRH3 having the sequence of SEQ ID NO: 315; and a light chain amino acid sequence that comprises a CDRL1 having the sequence of SEQ ID NO: 340, a CDRL2 having the sequence of SEQ ID NO: 344, and a CDRL3 having the sequence of SEQ ID NO:387; and wherein said second agent is pertuzumab, panitumumab, trastuzumab, or T-DM1.

2. The method of claim 1, wherein said first agent is an antigen-binding protein that binds to HER-3,comprising: (a) a heavy chain comprising the amino acid sequence of SEQ ID NO: 42, and a light chain comprising the amino acid sequence of SEQ ID NO: 44; (b) a heavy chain comprising the amino acid sequence of SEQ ID NO: 54 and a light chain comprising the amino acid sequence of SEQ ID NO: 56; (c) a heavy chain comprising the amino acid sequence of SEQ ID NO: 70 and a light chain comprising the amino acid sequence of SEQ ID NO: 72; (d) a heavy chain comprising the amino acid sequence of SEQ ID NO: 92 and a light chain comprising the amino acid sequence of SEQ ID NO: 94; or (e) a heavy chain comprising the amino acid sequence of SEQ ID NO: 96 and a light chain comprising the amino acid sequence of SEQ ID NO: 98.

3. The method of claim 1, wherein said first agent is an antigen-binding protein that binds to HER-3,and comprises the heavy chain amino acid sequence of SEQ ID NO: 42 and the light chain amino acid sequence of SEQ ID NO: 44.

4. The method of claim 1, wherein said first agent is an antigen-binding protein that binds to HER-3,and comprises the heavy chain amino acid sequence of SEQ ID NO: 54 and the light chain amino acid sequence of SEQ ID NO: 56.

5. The method of claim 1, wherein said first agent is an antigen-binding protein that binds to HER-3,and comprises the heavy chain amino acid sequence of SEQ ID NO: 70 and the light chain amino acid sequence of SEQ ID NO: 72.

6. The method of claim 1, wherein said first agent is an antigen-binding protein that binds to HER-3,and comprises the heavy chain amino acid sequence of SEQ ID NO: 92 and the light chain amino acid sequence of SEQ ID NO: 94.

7. The method of claim 1, wherein said first agent is an antigen-binding protein that binds to HER-3,and comprises the heavy chain amino acid sequence of SEQ ID NO: 96 and the light chain amino acid sequence of SEQ ID NO: 98.

8. The method of claim 1, wherein said antigen-binding protein is directed against the extracellular domain of HER-3.

9. The method of claim 1, wherein binding of said antigen-binding protein to HER-3 reduces HER-3-mediated signal transduction.

10. The method of claim 1, wherein binding of said antigen-binding protein to HER-3 reduces HER-3 phosphorylation.

11. The method of claim 1, wherein binding of said antigen-binding protein to HER-3 reduces cell proliferation.

12. The method of claim 1, wherein binding of said antigen-binding protein to HER-3 reduces cell migration.

13. The method of claim 1, wherein binding of said antigen-binding protein to HER-3 increases the downregulation of HER-3.

14. The method of claim 1, wherein said antigen-binding protein that binds to HER-3 is an antibody.

15. The method of claim 14, wherein said antibody is a monoclonal antibody, a recombinant antibody, a human antibody, a chimeric antibody, a multispecific antibody, or an antibody fragment thereof.

16. The method of claim 15, wherein said antibody fragment is a F(ab')2 fragment, a diabody, or a single chain antibody molecule.

17. The method of claim 14, wherein said antibody is of the IgG1-, IgG2-, IgG3- or IgG4-type.

18. The method of claim 1, wherein said first agent is an antigen-binding protein that binds to HER-3,and wherein said antigen-binding protein is coupled to an effector group.

19. The method of claim 18, wherein said effector group is a radioisotope or radionuclide, a toxin, or a therapeutic or chemotherapeutic group.

20. The method of claim 19, wherein said therapeutic or chemotherapeutic group is selected from the group consisting of calicheamicin, auristatin -PE, geldanamycin, maytansine and derivatives thereof.

21. The method of claim 1, wherein the second agent is trastuzumab.

22. The method of claim 1, wherein the second agent is panitumumab.

23. The method of claim 1, wherein the second agent is pertuzumab.

24. The method of claim 1, wherein the second agent is T-DM1.

25. The method of claim 1, optionally comprising administering a further therapeutic agent and/or radiation therapy.

26. The method of claim 25, wherein the further therapeutic agent is an anti-neoplastic agent.

27. The method of claim 25, wherein the anti-neoplastic agent is an anti-tumor antibody or a chemotherapeutic agent.

28. The method of claim 27, wherein the chemotherapeutic agent is selected from the group consisting of capecitabine, anthracycline, doxorubicin, cyclophosphamide, paclitaxel, docetaxel, cisplatin, gemcitabine, and carboplatin.

29. The method of claim 1, wherein said first agent and said second agent are administered by intravenous, subcutaneous, intramuscular or oral administration.

30. The method of claim 1, wherein said cancer is selected from the group consisting of breast cancer, ovarian cancer, prostate cancer, colon cancer, renal cancer, lung cancer, pancreatic cancer, head and neck cancer, epidermoid carcinoma, fibrosarcoma, melanoma, nasopharyngeal carcinoma, and squamous cell carcinoma.

31. The method of claim 1, comprising administering said first agent at a dose of about 1 to about 20 mg/kg body weight, at least once every 6 weeks.

32. The method of claim 1, comprising administering said second agent at a dose of about 1 to about 20 mg/kg body weight, at least once every 6weeks.

33. The method of claim 1, further comprising, prior to the administering, using a method that comprises analysis of a predictive marker to select a subject having a cancer associated with HER-3.

34. The method of claim 1, further comprising, after the administering, monitoring the therapeutic outcome.

35. A method of treating a cancer associated with HER-3 in a subject, comprising administering to the subject a first agent and a second agent, wherein said first agent is an antigen-binding protein that binds to HER-3 and comprises the heavy chain amino acid sequence of SEQ ID NO: 42 and the light chain amino acid sequence of SEQ ID NO: 44, and wherein said second agent is pertuzumab, panitumumab, trastuzumab, or T-DM1.

36. A method of treating a cancer associated with HER-3 in a subject comprising administering to the subject a first agent and a second agent, wherein said first agent is an antigen-binding protein that binds to HER-3, and comprises a heavy chain amino acid sequence selected from the group consisting of SEQ ID NOs: 42, 54, 70, 92, and 96, and a light chain, and wherein said second agent is pertuzumab, panitumumab, trastuzumab, or T-DM1.

37. A method of treating a cancer associated with HER-3 in a subject comprising administering to the subject a first agent and a second agent, wherein said first agent is an antigen-binding protein that binds to HER-3,and comprises a light chain amino acid sequence selected from the group consisting of SEQ ID NOs: 44, 56, 72, 94, and 98, and a heavy chain, and wherein said second agent is pertuzumab, panitumumab, trastuzumab, or T-DM1.

38. A method of treating a cancer associated with HER-3 in a subject, comprising administering to the subject a first agent and a second agent, wherein said first agent is an antigen-binding protein that binds to HER-3 and comprises the heavy chain amino acid sequence of SEQ ID NO: 70 and the light chain amino acid sequence of SEQ ID NO: 72, and wherein said second agent is pertuzumab, panitumumab, trastuzumab, or T-DM1.

Details for Patent 9,803,025

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 09/25/1998 ⤷  Try a Trial 2029-11-13
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 02/10/2017 ⤷  Try a Trial 2029-11-13
Amgen, Inc. VECTIBIX panitumumab Injection 125147 09/27/2006 ⤷  Try a Trial 2029-11-13
Genentech, Inc. PERJETA pertuzumab Injection 125409 06/08/2012 ⤷  Try a Trial 2029-11-13
Genentech, Inc. HERCEPTIN HYLECTA trastuzumab and hyaluronidase-oysk Injection 761106 02/28/2019 ⤷  Try a Trial 2029-11-13
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.